NCT02961283View on ClinicalTrials.gov

Study of ASN003 in Subjects With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
NeoplasmsMelanomaColorectal NeoplasmCarcinoma, Non-small Cell Lung
Interventions
DRUG

ASN003 ascending doses

DRUG

ASN003 MTD

The highest safe and well tolerated dose selected from the doses tested in Part A of the study.

Trial Locations (5)

33612

Moffitt Cancer Center, Tampa

49503

START MidWest, Grand Rapids

78229

South Texas Accelerated Research Therapeutics, San Antonio

90048

Cedars-Sinai Medical Center, Los Angeles

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Asana BioSciences
All Listed Sponsors
lead

Asana BioSciences

INDUSTRY